MarketCap
Facebook
X
Telegram
VistaGen Therapeutics Income Statement 2026-1999 | VTGN
Brief overview of financial performance at VistaGen Therapeutics
The conclusions below are based on five years of reported results. VistaGen Therapeutics reported revenue of $358 thousand in 2021 and $1.3 million by 2026. Across the full period, sales moved by +254.5%; the average annual rate was 28.8%. Revenue growth reflects a pronounced phase of business expansion.
The five-year EBITDA result moved by −590.2%: from −$10.4 million to −$71.9 million. Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −2911% to −5668%. A lower EBITDA share weakens the quality of the result.
Net income moved from −10.5 million dollars at the start to −69.7 million dollars at the end. Profitability deteriorated further over the five years.
Market capitalization changed from 9.4 million dollars to 21.7 million dollars (+129.8%). The valuation did not keep pace with the reported progress.
Conclusion
The indicators point to a weaker financial profile. The strongest signals are sales growth. The overall view is constrained by a low EBITDA margin, lower net income and a declining EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement VistaGen Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
21.7 M | 73.5 M | 73 M | 11.8 M | 11.7 M | 9.44 M | 19.3 M | 30.6 M | 13.9 M | 14.9 M | 15 M | 10.7 M | 10.5 M | 15.9 M | 36.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares |
38.1 M | 30.9 M | 19.4 M | 6.96 M | 6.89 M | 6.74 M | 43.9 M | 28.6 M | 13.9 M | 7.53 M | 1.77 M | 1.32 M | 1.1 M | 905 K | 737 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Historical Prices |
0.57 | 2.38 | 3.77 | 1.69 | 1.69 | 1.4 | 2.47 | 0.51 | 1.13 | 1.21 | 2.55 | 8 | 8 | 7.8 | 12.8 | 57 | ||||||||||||
Net Income |
-69.7 M | -51.4 M | -29.4 M | -59.2 M | -9.76 M | -10.5 M | -20.8 M | -24.6 M | -14.3 M | -10.3 M | -47.2 M | -13.9 M | -2.97 M | -12.9 M | -12.2 M | - | -4.12 M | -4.7 M | -5.45 M | -2 M | -1.77 M | -1.08 M | -8.76 M | -503 K | -2.11 M | -1.81 M | -700 K | -231 K |
Revenue |
1.27 M | 486 K | 1.06 M | 176 K | 180 K | 358 K | - | - | - | 1.25 M | - | - | - | 200 K | 1.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-72.1 M | -56 M | -33 M | -59.3 M | -9.77 M | -10.5 M | -20.8 M | -24.6 M | -14.2 M | -10.2 M | -17.9 M | -6.78 M | -5.03 M | -6.79 M | -9.04 M | -6.56 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | 13 K | 5 K | 5 K | 30.1 K | 8 K | 8.9 K | 4.6 K | 771 K | 4.55 M | -1.5 M | -921 K | 1.89 M | 3.12 M | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-71.9 M | -55.8 M | -32.9 M | -59.1 M | -9.61 M | -10.4 M | -20.7 M | -24.5 M | -14.1 M | -10.2 M | -17.8 M | -6.72 M | -4.97 M | -6.76 M | -9 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
73.4 M | 56.5 M | 34.1 M | 59 M | 9.95 M | 10.9 M | 20.8 M | 24.6 M | 14.2 M | 11.5 M | 17.9 M | 6.78 M | 5.03 M | 6.99 M | 10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
18.4 M | 17.1 M | 14.1 M | 14.7 M | 3.09 M | 3.12 M | 7.43 M | 7.46 M | 6.44 M | 6.3 M | 13.9 M | 4.34 M | 2.55 M | 3.56 M | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement VistaGen Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
42.2 M | 35.7 M | 31.9 M | 42.2 M | 35.7 M | 31.9 M | 30.6 M | 30.7 M | 30.6 M | 30.6 M | 7.38 M | 29.4 M | 10 M | 7.34 M | - | 6.89 M | 6.89 M | 6.89 M | 207 M | 202 M | 195 M | 192 M | 146 M | 81.1 M | 81.1 M | 67.1 M | 51.3 M | 43.2 M | 43.2 M | 42.6 M | 42.6 M | 30.7 M | 30.7 M | 25.8 M | 22.9 M | 13.9 M | 9.89 M | 9.03 M | 9.03 M | 8.38 M | 8.38 M | 8.04 M | 5.1 M | 1.77 M | 1.62 M | 1.62 M | 1.47 M | 1.3 M | 1.3 M | 1.28 M | - | 1.11 M | 1.08 M | 1.06 M | - | 18.3 M | 17.4 M | 16.8 M | 18.7 M | 16.4 M | 15.2 M | 15.2 M | 5.24 M |
Net Income |
-18.9 M | -19.4 M | -15.1 M | -18.9 M | -19.4 M | -15.1 M | -10.7 M | -14.1 M | -13 M | -10.7 M | -6.9 M | -6.35 M | -6.59 M | -6.9 M | - | -9.76 M | -17.5 M | -19.8 M | -16.7 M | -10.5 M | -31.1 M | -7.74 M | -6.21 M | -5.3 M | -5.3 M | -3.3 M | -3.13 M | -5.96 M | -5.96 M | -5.34 M | -6.21 M | -7.22 M | -7.22 M | -7.44 M | -4.08 M | -3 M | -5 M | -2.26 M | -2.27 M | -2.64 M | -2.64 M | -3.1 M | -1.97 M | -2.15 M | -2.15 M | -7.05 M | -29.5 M | -1.09 M | -1.09 M | -2.02 M | -4.55 M | 131 K | 131 K | -1.46 M | 186 K | -5.34 M | -5.34 M | -1.96 M | -1.83 M | -4.5 M | -4.5 M | -2.26 M | -2.41 M |
Revenue |
303 K | 258 K | 244 K | 303 K | 258 K | 244 K | 84 K | 234 K | 183 K | 84 K | 310 K | 411 K | 278 K | 177 K | - | - | - | 310 K | 39 K | 358 K | 1.07 M | 712 K | 442 K | 314 K | 314 K | 334 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.25 M | 1.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 200 K | 200 K | 200 K | 2 K | 2.4 K | 316 K | 555 K |
Operating Income |
-19.5 M | -20.1 M | -15.8 M | -19.5 M | -20.1 M | -15.8 M | -12.1 M | -15.1 M | -14.2 M | -12.1 M | -7 M | -7.88 M | -6.78 M | -7 M | - | -9.77 M | -17.5 M | -19.8 M | -16.7 M | -10.5 M | -31.1 M | -20.5 M | -6.22 M | -5.3 M | -5.3 M | -3.29 M | -3.12 M | -5.96 M | -5.96 M | -5.35 M | -6.22 M | -7.19 M | -7.19 M | -7.43 M | -4.08 M | -2.87 M | -4.99 M | -2.26 M | -2.26 M | -2.64 M | -2.64 M | -3.1 M | -1.96 M | -2.14 M | -2.14 M | -5.39 M | -1.82 M | -1.12 M | -1.12 M | -1.11 M | -1.27 M | -1.45 M | -1.45 M | -1.22 M | -1.3 M | -1.92 M | -1.92 M | -1.68 M | -1.72 M | -2.85 M | -2.85 M | -1.81 M | -1.6 M |
Interest Expense |
- | 6 K | -2 K | - | 6 K | -2 K | - | - | - | - | 97.2 K | 1.53 M | 192 K | 97.2 K | - | 5.3 K | 6.1 K | 2.3 K | 5 K | 5.1 K | 15.3 K | 10.2 K | 8 K | - | - | -3.9 K | -3.2 K | -1.5 K | -33.4 K | -31.9 K | 1 K | 1.8 K | 1.8 K | 2.9 K | 1 K | 2 K | 3 K | 3 K | 2.4 K | 1 K | 900 | 1.4 K | 1.4 K | 3 K | 2.5 K | 12.2 K | 755 K | 792 K | 792 K | 606 K | 785 K | -361 K | 361 K | 323 K | -316 K | -235 K | -235 K | -274 K | -103 K | -455 K | -456 K | -450 K | -732 K |
EBITDA |
-19.4 M | -20 M | -15.8 M | - | - | -15.8 M | -12.1 M | - | - | -12.1 M | -6.97 M | - | - | -6.97 M | - | -9.74 M | -17.4 M | -19.7 M | -16.7 M | -10.5 M | -31 M | -20.5 M | -6.22 M | -5.27 M | -5.27 M | -3.27 M | -3.12 M | -5.94 M | -5.89 M | -5.3 M | -6.2 M | -7.19 M | -7.13 M | -7.39 M | -4.08 M | -2.87 M | -4.99 M | -2.24 M | -2.26 M | -2.64 M | -2.6 M | -3.07 M | -1.96 M | -2.14 M | -2.1 M | -5.36 M | -1.82 M | -1.12 M | -1.08 M | -1.09 M | -1.27 M | -1.45 M | -1.41 M | -1.19 M | -1.3 M | -1.92 M | -1.9 M | -1.67 M | -1.72 M | -2.85 M | -2.82 M | -1.78 M | -1.6 M |
Operating Expenses |
19.8 M | 20.3 M | 16 M | 19.8 M | 20.3 M | 16 M | 12.2 M | 15.4 M | 14.4 M | 12.2 M | 7.18 M | 8.3 M | 7.06 M | 7.18 M | - | 9.95 M | 16.6 M | 20.1 M | 16.7 M | 10.9 M | 32.2 M | 21.3 M | 6.66 M | 5.61 M | 5.61 M | 3.63 M | 3.12 M | 5.96 M | 5.96 M | 5.35 M | 6.22 M | 7.19 M | 7.19 M | 7.43 M | 4.08 M | 2.87 M | 4.99 M | 2.26 M | 2.26 M | 3.89 M | 3.89 M | 3.1 M | 1.96 M | 2.14 M | 2.14 M | 5.39 M | 1.82 M | 1.12 M | 1.12 M | 1.11 M | 1.27 M | 1.45 M | 1.45 M | 1.22 M | 1.3 M | 1.92 M | 1.92 M | 1.68 M | 1.92 M | 2.85 M | 2.85 M | 2.12 M | 2.15 M |
General and Administrative Expenses |
5.63 M | 4.4 M | 4.37 M | 5.63 M | 4.4 M | 4.37 M | 4.57 M | 4.05 M | 4.2 M | 4.57 M | 2.98 M | 3.76 M | 3.21 M | 2.98 M | - | 3.09 M | 3.7 M | 4.79 M | 4.5 M | 3.12 M | 8.98 M | 5.86 M | 1.77 M | 2.12 M | 2.12 M | 1.27 M | 1.39 M | 2.95 M | 2.95 M | 1.15 M | 1.91 M | 1.86 M | 1.86 M | 2.17 M | 1.44 M | 1.27 M | 2.57 M | 1.16 M | 1.16 M | 2.28 M | 2.28 M | 1.49 M | 1.14 M | 1.34 M | 1.34 M | 3.73 M | 1.45 M | 671 K | 671 K | 556 K | 797 K | 897 K | 897 K | 546 K | 605 K | 799 K | 799 K | 576 K | 1.06 M | 1.55 M | 1.55 M | 895 K | 1.13 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company VistaGen Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
